| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Papadopoulos Stelios serves as a Director at EXEL and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 2 buys and 16 sells. Those positions are worth an estimated $557K at current prices.
Historically, Papadopoulos Stelios's trades have earned a middling insider score of 53/100 across 5 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -19.3%.
The biggest single holding is OVID (~$557K) as Director.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2017 | EXEL Exelixis, Inc. | Director | Sell | 200,000 | $27.68 | $5,535,387.30 | -16.2% | |
| Mar 20, 2017 | EXEL Exelixis, Inc. | Director | Sale+OE | 10,000 | $21.66 | $216,600.00 | -0.8% | |
| Jul 27, 2015 | BIIB Biogen Inc. | Director | Buy | 10,000 | $304.88 | $3,048,775.00 | -200.0% |